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Abstract
Background: Pulmonary adenocarcinomas with a micropapillary component having small papillary tufts and
lacking a central fibrovascular core are thought to result in poor prognosis. However, the component consists of
tumor cells often floating within alveolar spaces (aerogenous micropapillary component [AMPC]) rather than
invading fibrotic stroma observed in other organs like breast (stromal invasive micropapillary component [SMPC]).
We previously observed cases of lung adenocarcinoma with predominant SMPC that was associated with
micropapillary growth of tumors in fibrotic stroma observed in other organs. We evaluated the incidence and
clinicopathological characteristics of SMPC in lung adenocarcinoma cases.
Patients and Methods: We investigated the clinicopathological characteristics and prognostic significance of
SMPC in lung adenocarcinoma cases by reviewing 559 patients who had undergone surgical resection. We
examined the SMPC by performing immunohistochemical analysis with 17 antibodies and by genetic analysis with
epidermal growth factor receptor (EGFR) and KRAS mutations.
Results: SMPC-positive (SMPC(+)) tumors were observed in 19 cases (3.4%). The presence of SMPC was significantly
associated with tumor size, advanced-stage disease, lymph node metastasis, pleural invasion, lymphatic invasion,
and vascular invasion. Patients with SMPC(+) tumors had significantly poorer outcomes than those with SMPC-
negative tumors. Multivariate analysis revealed that SMPC was a significant independent prognostic factor of lung
adenocarcinoma, especially for disease-free survival of pathological stage I patients (p = 0.035). SMPC showed
significantly higher expression of E-cadherin and lower expression of CD44 than the corresponding expression
levels shown by AMPC and showed lower surfactant apoprotein A and phospho-c-Met expression level than
corresponding expression levels shown by tumor cell components without a micropapillary component. Fourteen
cases with SMPC(+) tumors (74%) showed EGFR mutations, and none of them showed KRAS mutations.
Conclusions: SMPC(+) tumors are rare, but they may be associated with a poor prognosis and have different
phenotypic and genotypic characteristics from those of AMPC(+) tumors.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/9433341526290040.
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A new lung adenocarcinoma classification system has
been proposed by the International Association for the
Study of Lung Cancer, American Thoracic Society, and
European Respiratory Society (IASLC/ATS/ERS) [1]. In
this classification, the micropapillary component (MPC)
was recommended as a new subtype of lung adenocarci-
noma in addition to the lepidic, acinar, papillary, and
solid subtypes defined in the 2004 World Health Orga-
nization (WHO) classification [2]. MPC was defined as
tumor cells growing in papillary tufts lacking fibrovascu-
lar cores and may float within alveolar spaces. MPC-pre-
dominant lung adenocarcinoma shows a high incidence
of nodal metastasis and a poor prognosis [3-8]. MPC-
predominant carcinomas developing in various other
organs, such as the breast and urinary bladder, known
as invasive micropapillary carcinoma, also have a poor
prognosis. However, localization of MPC in the lungs is
significantly different from that in the other organs;
MPC in lung adenocarcinoma is distinguished by float-
ing tumor cells within alveolar spaces (aerogenous
micropapillary component, AMPC), while MPC in other
organs has been observed primarily in the stroma as
invasive components (stromal invasive micropapillary
component, SMPC) [3,4].
Few studies have examined lung adenocarcinoma with
SMPC [9,10]. Recently, we reported 2 cases of SMPC-
predominant lung adenocarcinoma [9]. The proportion
of SMPC in both tumors was greater than 50% in area.
We observed that SMPC had a strong association with
vascular invasion, similar to the cases of SMPC-predo-
minant carcinoma in other organs. However, a large-
scale investigation on pulmonary SMPC has not been
conducted.
The aims of this study included: (1) clarifying the inci-
dence of SMPC in lung adenocarcinoma; (2) elucidating
the clinicopathological characteristics of the tumor; and
(3) determining the prognoses of the SMPC-positive
(SMPC(+)) tumors and comparing them with those of
SMPC-negative (SMPC(-)) tumors. We reviewed 559
resected lung adenocarcinomas for this study with per-
forming immunohistochemical and genetic analysis.
Methods
Patients
We analyzed 565 consecutive cases of primary lung ade-
nocarcinoma treated by surgical resection at the Kana-
gawa Cancer Center between February 2007 and
December 2010. Formalin fixation of the resected lung
tissue was performed within 48 hours to reduce the loss
of immunohistochemical antigen expression and degen-
eration of DNA. Six patients who had received preo-
perative chemotherapy were excluded. A total of 559
cases were enrolled in the study. The median follow-up
time was 634.5 days (range, 28-1512 days). All patients
provided informed consent, and the studies were per-
formed according to the requirements of the institu-
tional review board of Kanagawa Cancer Center.
Pathological review
Excised specimens were fixed in a solution of 10% buf-
fered formaldehyde, and the sections were embedded in
paraffin. Next, 4-μm-thick sections, including the largest
cut surface of the tumor, were prepared and stained
using hematoxylin and eosin (HE) as well as alcian blue
and elastica-van-Gieson (AB-EVG) to detect cytoplasmic
mucin production and the elastic fiber framework. Lym-
phatic invasion and pulmonary metastasis were evalu-
ated on HE sections. Vascular and pleural invasion was
evaluated in AB-EVG sections. Sections were reviewed
by 2 observers (M.O. and T.Y.) who were unaware of
the clinical data. Tumor size was measured as the maxi-
mal diameter on the cut sections of the lung. Pathologi-
cal stage was determined based on the criteria of the 7
th
TNM classification of Union of International Cancer
Control [11].
Histological definition of micropapillary components
Histopathological diagnosis of lung adenocarcinoma was
determined according to the IASLC/ATS/ERS interna-
tional multidisciplinary classification of lung adenocarci-
noma [1]. Comprehensive histological subtyping was
performed on the primary tumor and divided by percen-
tage into 5 distinctive subtypes: lepidic, acinar, papillary,
micropapillary, and solid, totaling 100% per tumor. We
defined the subtype as positive when it occupied at least
1% of the entire tumor. We classified a micropapillary
subtype into 2 components, AMPC and SMPC, using
the following criteria: AMPC is widely recognized in the
lungs as tumor cells floating within alveolar spaces, and
SMPC includes papillary components consisting of tufts
lacking central fibrovascular cores, surrounded by lacu-
nar spaces and identified as invasive components in the
stroma as previously described [9] (Figure 1A and 1B).
Additionally, a tumor area without micropapillary com-
ponents was defined as a non-micropapillary component
(nMPC).
Tumor tissue microarray (TMA) synthesis
TMAs were constructed using a manual tissue-arraying
instrument (KIN-4; Azumaya, Tokyo, Japan) as pre-
viously described [12], and specimens were punched
using a stylet 3 mm in diameter.
Immunohistochemistry
The 17 antibodies used for immunohistochemical char-
acterization of tumor cells in TMA in this study are
listed in Table 1. Immunohistochemical staining was
Ohe et al. Diagnostic Pathology 2012, 7:3
http://www.diagnosticpathology.org/content/7/1/3
Page 2 of 11Figure 1 Microscopic features of micropapillary component in the lung adenocarcinoma stained with hematoxylin-eosin (HE). A, AMPC.
AMPC is the micropapillary component in which tumor cells are floating within alveolar spaces. B, SMPC. SMPC are tumor cells observed in the
stroma and consisting of a papillary component with a tuft lacking central fibrovascular cores surrounded by lacunar spaces. (A, B: upper panel:
magnification, ×100; lower panel: magnification, ×400) SMPC, stromal micropapillary component; AMPC, aerogenous micropapillary component.
Table 1 Antibodies
Classification/Antibody Clone Dilution Source
Cellular adhesion molecules
E-cadherin NCH-38 1:100 DakoCytomation, Carpinteria, CA, USA
CD44 DF1485 1:400 Novocastra, Newcastle upon Tyne, UK
Laminin5g2 4G1 1:50 DakoCytomation, Glostrup, Denmark
Growth factor
VEGF-C Polyclonal 1:50 Abcam, Cambridge, UK
Apoptosis-associated proteins
bcl2 124 1:50 DakoCytomation, Glostrup, Denmark
p53 DO-7 Pre-diluted Nichirei, Tokyo, Japan
cleaved caspase-3 Polyclonal 1:400 Cell signaling, Danvers, MA, USA
Mucin-related proteins
MUC1 Ma695 1:100 Novocastra, Newcastle upon Tyne, UK
MUC6 CLH5 1:100 Novocastra, Newcastle upon Tyne, UK
Hypoxia induced protein
HIF-1a EP1215Y 1:500 Abcam, Cambridge, UK
Others
TTF-1 8G7G3/1 1:100 DakoCytomation, Carpinteria, CA, USA
SP-A PE10 1:100 Dako, Kyoto, Japan
Vimentin V9 Pre-diluted DakoCytomation, Carpinteria, CA, USA
Ki-67 MIB-1 1:50 Dako, Glostrup, Denmark
LYVE1 15A5B2 1:400 Oriental Yeast, Tokyo, Japan
c-Met EP1454Y 1:200 Abcam, Cambridge, UK
Phospho-c-Met Polyclonal 1:800 Stressgen, Ann Arbor, MI, USA
VEGF-C, vascular endothelial growth factor-C; HIF-1a, hypoxia induced factor 1-a; TTF-1, thyroid transcription factor-1; SP-A, surfactant apoprotein A; LYVE1,
lymphatic vessel endothelial hyaluronan receptor 1.
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into 4-μm-thick sections and mounted on silane-coated
slides. HE staining was performed on initial sections to
verify histology. The remaining sections were deparaffi-
nized in xylene and dehydrated in a graded alcohol ser-
ies, and endogenous peroxidase was blocked using 3%
hydrogen peroxide in absolute methyl alcohol. Heat-
induced epitope retrieval was performed for 20 min at
95°C in 0.02 mol/L citrate buffer (pH 6.0) in samples
fixed with 10% formalin if necessary. The slides were
rinsed using deionized water and incubated with pri-
mary antibodies. They were then washed 3 times in
phosphate-buffered saline and incubated with EnVision+
System-HRP (DAKO, Glostrup, Denmark). The reaction
products were visualized using 3-3’-diaminobenzidine
tetrahydrochloride, and sections were counterstained
using hematoxylin. Additionally, a similar staining
method was used for anti-podoplanin antibody (clone
D2-40, pre-diluted; Ventana, Tucson, AZ, USA) to eval-
uate lymphatic permeation.
Calculation of staining scores
Immunostaining was scored based on staining intensity
and percentage of positively stained cells, with 2 obser-
vers evaluating immunostained samples independently.
When the observers gave different scores to immunos-
tained samples, the slides were reviewed together under
a multiheaded microscope until a consensus was
reached. Sections were classified by staining intensity as
negative (total absence of staining), 1+ (weak staining), 2
+ (moderate staining), or 3+ (strong staining). Staining
scores were calculated by multiplying the percentage of
positive tumor cells per section (0-100%) by the staining
intensity; scores obtained ranged from 0 to 300. Expres-
sion of p53, cleaved caspase-3, and Ki-67 were deter-
mined by counting 300 tumor cells under a high power
field (×400) and results are shown as the percentage of
positive cells.
Mutation analysis
Mutation analyses of EGFR gene exons 19 and 21 and
KRAS gene codons 12 and 13 were performed using
loop-hybrid mobility shift assays and gene sequencing
procedures described elsewhere [13].
Statistical analysis
All calculations were performed using SPSS software
(Dr. SPSS II for Windows Standard version 11.0; SPSS
I n c . ,C h i c a g o ,I L ,U S A ) .T h eChi-square for indepen-
dence or Fisher’s exact probability test was performed to
analyze differences in patient characteristics between the
2g r o u p s .T h eF i s h e r ’s exact probability test was per-
formed if there were 5 or fewer observations in a group.
For univariate analysis, all cumulative survival was
estimated using the Kaplan-Meier method, and differ-
ences in variables were calculated using the log-rank
test. Multivariate regression analysis was conducted
according to the Cox proportional hazard model. The
Mann-Whitney U test was used to compare staining
scores. Differences were considered significant when the
P value was less than 0.05.
Results
Clinicopathological characteristics of patients with SMPC
Figure 2 shows a Venn diagram of the relationship
between the micropapillary component sets in the 559
patients examined in this study. SMPC was observed in
19 patients (3.4%) and AMPC in 99 (17.7%) patients. A
mixture of SMPC and AMPC was observed in 14
patients, pure SMPC without AMPC in 5 patients, and
pure AMPC without SMPC in 85 patients. A micropa-
pillary pattern was observed in 50-100% in 2 SMPC
tumor and less than 50% in 17 SMPC tumors. No
S M P C ( + )t u m o r sw e r ec o m p l e t e l yr e p l a c e db yS M P C .
Clinicopathological characteristics of patients with
SMPC(+) and SMPC(-) tumors are summarized in
Table 2. Patients with SMPC(+) tumors were signifi-
cantly found to be at a more advanced stage, larger than
30 mm in diameter, and have more frequent lymph
node metastasis compared to those with SMPC(-)
tumors. Pleural, lymphatic, and vascular invasion were
observed more often in patients with SMPC(+) tumors
than in those with SMPC(-) tumors. (68% vs. 17%, P <
0.001; 74% vs. 15%, P < 0.001; 74% vs. 22%, P <0 . 0 0 1 ,
respectively). No significant differences in age, gender,
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Figure 2 Venn diagram of patients included in the present
study. Among the 559 cases of lung adenocarcinoma, 104 cases
had MPC. Nineteen cases had SMPC (SMPC(+) tumors, the area
enclosed by continuous line), and 99 had AMPC (AMPC(+) tumors,
the area enclosed by dotted line). A mixture of SMPC and AMPC
was observed in 14 patients, SMPC without AMPC in 5 and AMPC
without SMPC in 85. MPC, micropapillary component; SMPC, stromal
micropapillary component; AMPC, aerogenous micropapillary
component.
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Page 4 of 11or smoking status were observed between patients with
SMPC(+) and SMPC(-) tumors.
Survival analysis
Among all stage patients, median follow-up time was
654 days (range, 33-1512 days) in SMPC(-) tumors, 240
days (range, 28-661 days) in SMPC(+) tumors, 664 days
(range, 28-1512 days) in AMPC(-) tumors, and 467 days
(range, 36-1412 days) in AMPC(+) tumors. Among the
stage I patients, median follow-up time was 767 days
(range, 59-1343 days) in SMPC(-) tumors, 192 days
(range, 227-485 days) in SMPC(+) tumors, 767 days
(range, 59-1343 days) in AMPC(-) tumors, and 836 days
(range, 140-1233 days) in AMPC(+) tumors. Recurrence
occurred in 28 of 559 cases. SMPC(+) tumors recurred
i n4o f1 9i na l ls t a g ea n di n2o f1 0i np - s t a g eI ,a n d
AMPC(+) tumors recurred in 8 of 99 cases and 4 of 69
cases, respectively. In all stage, disease-free survival
(DFS) of patients with SMPC(+) tumors was signifi-
cantly poorer than that in patients with SMPC(-) tumors
(Figure 3A, P < 0.001); the same result was observed in
patients with AMPC(+) and AMPC(-) tumors (Figure
3B, P = 0.045,). In p-stage I patients, DFS of those with
SMPC(+) tumors showed significantly poorer outcome
than that of patients with SMPC(-) tumors (Figure 3C,
P < 0.001); the same result was observed between
patients with AMPC(+) and AMPC(-) tumors (Figure
3D, P = 0.023).
In univariate analysis, high pathological stage (P <
0.001), pleural invasion (P < 0.001), lymphatic invasion (P
< 0.001), vascular invasion (P < 0.001), SMPC(+) (P <
0.001), and AMPC(+) tumors (P =0 . 0 4 5 )s h o w e da n
unfavorable influence on survival for all stage, and pleural
invasion (P < 0.001), lymphatic invasion (P < 0.001), vas-
cular invasion (P < 0.001), SMPC(+) (P < 0.001), and
AMPC(+) tumors (P = 0.023) showed an unfavorable
influence on survival for p-stage I (Table 3, 4). In multi-
variate analysis, pathological stage (P = 0.028), lymphatic
invasion (P = 0.009), and vascular invasion (P =0 . 0 1 1 )
were identified as significant independent prognostic fac-
tors for all stage (Table 3). Though not observed for all
stage, the presence of SMPC(+) tumors (P = 0.035) was
identified as a significant independent prognostic factor
for p-stage I, as well as lymphatic invasion (P =0 . 0 2 0 )
and vascular invasion (P = 0.049) (Table 4). The presence
of AMPC(+) tumors was not a significant prognostic fac-
tor for all stage or p-stage I.
Immunohistochemical findings
We evaluated immunohistochemical profiles of SMPC,
AMPC, and nMPC. These lesions were evaluated in
TMAs for 33 cases, including 19 SMPC(+) tumors and
14 pure AMPC tumors. The latter 14 tumors were
selected from 85 pure AMPC tumors according to
operation date, patient age, gender, and smoking status
to match clinical background factors between SMPC
and AMPC. nMPC was generally included in TMA
cores of SMPC and AMPC. The total number of TMA
was 19 SMPC and 28 AMPC. Staining scores are sum-
marized in Table 5.
In cellular adhesion molecules, E-cadherin staining
scores in patients with SMPC, AMPC, and nMPC were
Table 2 Clinicopathological characteristics of patients
with SMPC
all % SMPC P value
(-) % (+) %
No. 559 540 97 19 3
Age
Median 67 67 67 0.219*
Range 23-87 23-87 40-76
Gender
Female 288 52 282 52 6 32 0.077**
Male 271 48 258 48 13 68
Smoking status
Nonsmoker 284 51 276 51 8 42 0.596**
Smoker 275 49 264 49 11 58
BI Average 369 364 502
Tumor size
Average(mm) 25 25 35
Range(mm) 5-140 5-140 15-75
< 30 mm 396 71 388 72 9 47 < 0.001*
≥ 30 mm 163 29 152 28 10 53
Pathological stage
IA 363 65 360 67 4 21 < 0.001**
IB 95 17 88 16 6 32
IIA 36 6 31 6 5 26
IIB 13 2 13 2 0 0
IIIA 42 8 39 7 3 16
≥ IIIB 10 29215
Lymph node metastasis
NX 69 12 68 13 1 5
N0 420 75 409 75 11 58 0.002**
≥ N1 70 13 63 12 7 21
Pleural invasion
Negative 452 80 446 83 6 32 < 0.001**
Positive 107 20 94 17 13 68
Lymphatic invasion
Negative 466 83 461 85 5 26 < 0.001**
Positive 93 17 79 15 14 74
Vascular invasion
Negative 427 76 422 78 5 26 < 0.001**
Positive 132 24 118 22 14 74
* Mann-Whitney’s U test
** Chi-square for independence test
No., number of patients; BI, Brinkman index = (number of cigarettes per day)
× (duration of years); SMPC, stromal micropapillary component; AMPC,
aerogeneous micropapillary component
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Page 5 of 11215.3, 143.9, and 187.1, respectively, and although the
differences were not significant between patients with
SMPC or nMPC and between patients with AMPC or
nMPC (P = 0.312, 0.127, respectively), staining scores of
SMPC were significantly higher than those for patients
with AMPC (P = 0.020) (Figure 4A-C). CD44 staining
scores in SMPC, AMPC, and nMPC were 60.8, 205.9,
and 141.3, respectively. The CD44 expression level in
SMPC was significantly lower than in AMPC (P <
0.001) and significantly higher than that in nMPC
lesions (P = 0.015) (Figure 4D-F).
For other antibodies, staining scores of surfactant apo-
protein A (SP-A) in the SMPC, AMPC, and nMPC were
45.2, 82.6, and 123.2, respectively, and although the dif-
ference was not significant between AMPC and nMPC
(P = 0.203), the staining score in SMPC was significantly
lower than those in nMPC (P = 0.024) (Figure 4G-I).
Similarly, staining scores of phospho-c-Met in SMPC,
AMPC, and nMPC were 34.2, 50.5, 88.0, respectively,
and staining scores in SMPC were significantly lower
than those in nMPC (Figure 4J-L).
Mutation analysis
Mutation analysis was performed in 33 patients for
whom TMAs were constructed for immunohistochem-
ical analysis. Table 6 summarizes the results of the
mutation analysis. Although no cases examined pos-
sessed the KRAS mutations, EGFR mutations were
detected in 20 cases (61%): 14 in patients with SMPC(+)
tumors (74%) and 6 in patients with SMPC(-) tumors
(43%). There was no significant association between the
existence of SMPC and EGFR mutations. Among the 20
cases with EGFR mutations, 7 had deletions at exon 19,
13 had a point mutation at exon 21, and there were no
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Figure 3 Cumulative disease-free survival rates of patients according to presence of SMPC and AMPC. A, B are cumulative disease-free
survival rates in all stage, and C, D are that of in p-stage I. Cumulative disease-free survival rates stratified by presence of SMPC are shown in A
and C, and those stratified by presence of AMPC are shown in B and D. In all stage and in p-stage I, SMPC(+) tumors and AMPC(+) tumors had
significantly poorer outcomes. Outcomes of SMPC(+) tumors were more significantly negative than those of AMPC(+) tumors. SMPC, stromal
micropapillary component; AMPC, aerogenous micropapillary component.
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Page 6 of 11multiple mutations. Among the 13 cases with a point
mutation at exon 21, 12 had an L858R mutation and
one had an L861Q mutation.
Discussion
The present study revealed the incidence of SMPC(+)
lung adenocarcinoma in consecutive surgical cases to be
3.4%, which is lower than that of AMPC(+) lung
adenocarcinoma (17.7%). In non-pulmonary organs, the
incidence of invasive micropapillary carcinoma was
reported to be 7% in breast carcinoma [14], 0.9% in
urinary bladder cancer [15], and 9.4% in colon cancer
[16]. Generally, invasive micropapillary carcinomas
occur infrequently in any organ.
Prognosis of lung adenocarcinoma with MPC has been
reported to be worse and have the potential for high
malignancy [17,18], but no studies have separately evalu-
ated SMPC and AMPC. We showed that SMPC(+)
Table 3 Impact of potential prognostic factors on DFS of
patients of lung adenocarcinoma in all stage by
univariate and multivariate analysis
No. % Univariate
analysis
Multivariate analysis
P value Hazard
ratio
95% CI P
value
Total 559
Age
< 65 213 38 0.388 1.000
≥ 65 346 62 1.933 0.849-4.402 0.116
Gender
Female 288 52 0.768 1.000
Male 271 48 0.807 0.232-2.803 0.735
Smoking status
Non-
smoker
284 49 0.560 1.000
Smoker 275 51 1.164 0.342-3.956 0.808
Tumor size
< 30 mm 396 71 0.059 1.000
≥ 30 mm 163 29 0.819 0.338-1.985 0.658
Pathological
stage
I 458 82 <0.001 1.000
II, III, IV 101 18 2.768 1.113-6.884 0.028
Pleural invasion
Negative 452 81 <0.001 1.000
Positive 107 19 0.848 0.345-2.083 0.719
Lymphatic
invasion
Negative 466 83 <0.001 1.000
Positive 93 17 3.430 1.363-8.634 0.009
Vascular
invasion
Negative 427 76 <0.001 1.000
Positive 132 24 3.309 1.312-8.350 0.011
SMPC
Negative 540 97 <0.001 1.000
Positive 19 3 1.871 0.528-6.630 0.332
AMPC
Negative 460 83 0.045 1.000
Positive 99 17 1.132 0.450-2.845 0.792
DFS, disease free survival; No., number of patients; SMPC, stromal
micropapillary component; AMPC, aerogeneous micropapillary component; CI,
confidence interval.
Table 4 Impact of potential prognostic factors on DFS of
patients of lung adenocarcinoma in p-stage I by
univariate and multivariate analysis
No. % Univariate
Analysis
Multivariate analysis
P value Hazard
ratio
95% CI P
value
Total 458
Age
< 65 172 38 0.394 1.000
≥ 65 286 62 2.191 0.474-10.131 0.316
Gender
Female 249 54 0.063 1.000
Male 209 46 0.157 0.014-1.787 0.136
Smoking status
Non-
smoker
248 54 0.204 1.000
Smoker 210 46 0.768 0.117-5.052 0.784
Tumor size
< 30 mm 358 78 0.264 1.000
≥ 30 mm 100 22 0.304 0.037-2.504 0.268
Pleural
invasion
Negative 402 88 < 0.001 1.000
Positive 56 12 1.519 0.328-7.040 0.593
Lymphatic
invasion
Negative 415 91 < 0.001 1.000
Positive 43 9 5.016 1.295-19.434 0.020
Vascular
invasion
Negative 390 85 < 0.001 1.000
Positive 68 15 4.494 1.006-20.081 0.049
SMPC
Negative 448 98 < 0.001 1.000
Positive 10 2 9.028 1.164-70.031 0.035
AMPC
Negative 389 98 0.023 1.000
Positive 69 2 1.825 0.378-8.808 0.454
DFS, disease free survival; No., number of patients; SMPC, stromal
micropapillary component; AMPC, aerogeneous micropapillary component; CI,
confidence interval.
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several biological factors including tumor size, lymph
node metastasis, advanced stage disease, and pleural and
lymphovascular invasion. Univariate analysis also
r e v e a l e dt h ep r e s e n c eo fS M P Ca n dA M P Ca sas i g n i f i -
cant predictor of unfavorable outcome. However, the
most remarkable finding was observed in multivariate
analysis: among the patients in p-stage I, patients with
not AMPC but SMPC showed a significantly poorer
DFS than those without MPC. We used immunohisto-
chemistry with monoclonal antibody D2-40 against lym-
phatic endothelium in TMA specimens and found that
lymphatic vessels are involved within SMPC areas in 4
(21%) of 19 SMPC(+) tumors (data not shown). When
compared with AMPC(+) tumors, SMPC(+) tumors
significantly more often showed pleural, lymphatic, and
vascular invasion than AMPC(+) tumors (68% vs. 33%,
P = 0.004; 74% vs. 30%, P < 0.001; 74% vs. 41%, P =
0.010, respectively). Therefore, these data suggest that a
strong association between SMPC(+) tumors and pleural
and lymphovascular invasion may in part explain their
aggressive behavior.
Moreover, we investigated the immunohistochemical
differences between SMPC and AMPC. In the study, we
observed high E-cadherin expression and low CD44
expression in SMPC. Phospho-c-Met expression gener-
ally decreases in SMPC to a greater extent than in
AMPC. Recently, it has been suggested that E-cadherin
repression and CD44 expression are associated with the
epithelial-mesenchymal transition (EMT), which was
thought to lead to tumor invasion [19,20]. Additionally,
Elliot et al. reported that hepatocyte growth factor
(HGF) and c-Met signaling promotes EMT in breast
cancer [21], and Orian-Rousseau et al. reported that
CD44 is strictly required for c-Met activation by HGF in
human carcinoma [22]. Consistent with these data, EMT
may not occur in SMPC despite its existence in the
stroma, or invasion of SMPC may occur through a dif-
ferent invasion mechanism from EMT. Our immunohis-
tochemical findings of SMPC showed lower expression
of SP-A than that of nMPC. Many studies have reported
that SP-A deletion is correlated with patient survival,
and reduced SP-A in MPC may be an excellent indica-
tor for poor prognosis in small-size lung adenocarci-
noma [23,24]. Reduced SP-A may contribute to an
unfavorable outcome of SMPC(+) tumors.
Some studies have reported a significant association
between the presence of MPC and EGFR mutations and
effectiveness of EGFR tyrosine kinase inhibitor (EGFR-
TKI) for MPC(+) tumors [25-28]. Since SMPC of lung
adenocarcinoma may be associated with a high inci-
dence of EGFR mutations, EGFR-TKI may be effective
against SMPC(+) tumors. Patients with these pathologi-
cal features of lung adenocarcinoma may benefit from
EGFR-TKI as postoperative chemotherapy or first-line
chemotherapy of relapsed lung adenocarcinoma.
In conclusion, we observed SMPC(+) adenocarcinoma.
The incidence of SMPC(+) tumors is low, and SMPC(+)
tumors have a different prognostic impact compared to
AMPC(+) tumors. Particularly for the early stage
tumors, SMPC(+) tumors have different pathobiological
characteristics from AMPC(+) tumors, and SMPC(+)
tumors frequently contain the EGFR mutation. There-
fore, it is important to determine the presence of SMPC
in lung adenocarcinoma, particularly p-stage I tumors,
and the presence of SMPC should be noted in a pathol-
ogy report to alert the clinician to the possibility of poor
prognosis.
Table 5 Staining Scores in SMPC, AMPC and nMPC
lesions
Classification/Antibody SMPC AMPC nMPC
Cellular adhesion molecules
E-cadherin 215.3* 143.9 187.1
CD44 60.8
‡ 205.9
¶ 141.3
Laminin5g2 69.4 36.9 60.3
Growth factor
VEGF-C 294.4 296.4 282.1
Apoptosis-associated proteins
bcl2 13.2 11.1 21.8
p53
§ 36.4 26.1 45.0
cleaved caspase-3
§ 0.3 0.2 0.4
Mucin-related proteins
MUC1 169.7 182.5 202.1
MUC6 0.0 0.0 0.0
Hypoxia induced protein
HIF-1a 1.8 2.4 2.9
Others
TTF-1 267.9 289.3 248.6
SP-A 45.2
‡ 82.6 123.2
Vimentin 112.1 117.9 72.1
Ki-67
§ 22.6 16.9 16.2
LYVE1 98.9 107.2 101.9
c-Met 217.2 253.8 211.4
Phospho-c-Met 34.2
‡ 50.0 88.0
SMPC, stromal micropapillary component; AMPC, aerogeneous micropapillary
component; nMPC, non-micropapillary component; VEGF-C, vascular
endothelial growth factor-C; HIF-1a, hypoxia induced factor 1-a; TTF-1, thyroid
transcription factor-1; SP-A, surfactant apoprotein A; LYVE1, lymphatic vessel
endothelial hyaluronan receptor 1.
§ Positivity rate of positive tumor cells in 300 tumor cells (percentage).
* The difference in staining scores between SMPC and AMPC is statistically
significant (P = 0.020).
‡ The differences in staining scores between SMPC and nMPC are statistically
significant for CD44 (P = 0.011), and SP-A (P = 0.024) and phospho-c-Met (P =
0.011) expression.
¶ The difference in staining scores between AMPC and nMPC is statistically
significant (P = 0.015).
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Page 8 of 11Figure 4 Photomicrographs of immunohistochemistry. E-cadherin (A-C); CD44 (D-F); SP-A (G-I); Phospho-c-Met (J-L).C o m p a r e dw i t h
AMPC, increased E-cadherin and decreased CD44 membrane immunostaining were found in SMPC. Moreover, SP-A cytoplasm and Phospho-c-
Met membrane immunostaining were decreased in SMPC (×400). SMPC, stromal micropapillary component, left panels; AMPC, aerogenous
micropapillary component, middle panels; nMPC, non-micropapillary component, right panels.
Table 6 Mutation analysis
total % SMPC(+) cases % SMPC(-) cases % P value
No. 33 19 14
EGFR mutation
Negative 13 39 5 26 8 57 0.076*
Positive 20 61 14 74 6 43
ex19 7 35
§ 53 6
§ 23 3
§ 0.664*
ex21 13 65
§ 96 4
§ 46 7
§
KRAS mutation
Negative 33 100 19 100 14 100 -
Positive 0 0 0 0
No., number of patients; EGFR, epidermal growth factor receptor; SMPC, stromal micropapillary component
* Fisher’s exact probability test
§ Rate of positive cases at ex19 and 21 in EGFR mutation positive cases, respectively.
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